Benitec Biopharma Limited (ASX:BLT)
Chief Business Officer Carl Stubbings presents at ASX Spotlight Series in New York.
The biotechnology company’s presentation is titled, “Gene Silencing: A quiet revolution in healthcare”.
Mr Stubbings provides a financial snapshot and investment case for Benitec Biopharma while outlining the group’s operations.
Summarising the presentation Mr Stubbings says, “We are developing a technology... with our lead indication TT 034 being a disruptive technology in what we believe will remain a significant market.
Potentially we can provide a cure for a wide range of diseases; we have over 100 patents around the technology and specific diseases themselves.
We have an extensive pipeline of programs, as I’ve said previously, any one of which could be a company maker.”